APPA C2013-01

A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Phase 3 Study of APF530 500mg SC, Fosprepitant 150mg IV, and Dexamethasone vs Ondansetron 0.15mg/kg IV, Fosaprepitant 150mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy (HEC).